Transmitted Minority Drug-Resistant HIV Variants: A New Epidemic? by Deeks, Steven G
PLoS Medicine  |  www.plosmedicine.org 1014 July 2008  |  Volume 5  |  Issue 7  |  e164
Perspective
D
espite high rates of viral 
turnover and viral evolution, 
HIV has proven to be 
surprisingly easy to suppress with 
combination antiretroviral therapy 
(ART) in the regions of the world 
where such treatment is available. 
Recent reports indicate that the vast 
majority of patients initiating ART 
should be able to achieve durable if 
not indefinite viral suppression [1]. 
Given that there are now over 20 
antiretroviral drugs from six unique 
classes, even if one regimen fails, 
others are often readily available. The 
emerging consensus among clinicians 
and clinical investigators is that fewer 
and fewer patients will generate highly 
resistant HIV during the course of their 
treatment. 
Transmitted Antiretroviral Drug 
Resistance
As the prevalence of drug resistance 
among long-term treated patients 
wanes, concerns are now turning to 
those treatment-naïve patients who 
may have acquired drug resistance 
from their partners. There are two 
ways in which they can acquire such 
resistance—either at the time of 
primary infection or (less commonly) 
after a “superinfection” event (i.e., a 
person with HIV becomes infected 
with a second, drug-resistant HIV 
strain) [2,3]. Using standard “bulk 
sequencing” genotypic assays, 
researchers have found that the 
percentage of treatment-naïve patients 
with detectable levels of antiretroviral 
drug resistance has been stable in the 
5% to 15% range [4–8]. Given this 
high prevalence of resistance, most 
guideline panels now recommend the 
use of genotypic resistance testing prior 
to the introduction of ART.
 Several lines of evidence suggest 
that the reported prevalence of drug 
resistance among treatment-naïve 
individuals under-represents the true 
scope of the issue. In the absence 
of selective pressure exerted by 
antiretroviral drugs, drug resistance 
mutations often wane to low levels, 
presumably as these mutations 
negatively affect viral replicative fitness 
[9,10]. Hence, it is likely that by the 
time individuals present clinically, 
resistance mutations may have declined 
below readily detectable levels, 
although they will persist indefinitely 
in the “latent reservoir.” Also, acute 
HIV infection is often associated with 
the transmission of multiple distinct 
variants, some of which may persist at 
very low levels [11]. 
To determine if low-level (or 
“minority”) drug-resistant variants of 
HIV exist in untreated individuals, 
Jeffrey Johnson and colleagues 
developed and validated a highly 
sensitive real-time polymerase chain 
reaction assay that can detect certain 
drug resistance mutations, even when 
such mutations are present in less than 
1% of the plasma virus population [12]. 
This assay was so sensitive that it risked 
detecting mutations that emerge as a 
consequence of natural (unselected) 
variation [13]. In an elegant series 
of studies aimed at validating their 
assay, reported in PLoS ONE, Johnson 
et al. applied this assay to a cohort of 
individuals from the pre-antiretroviral 
drug era and established specific 
levels above which the detection of 
any mutation would likely reflect 
the presence of a drug-selected virus 
population [12]. 
As reported in the current issue of 
PLoS Medicine, Johnson and colleagues 
next applied this assay to several 
distinct cohorts [14]. Two novel and 
important findings were reported. 
First, among a cohort of 205 HIV-
infected, treatment-naïve individuals 
in Los Angeles and Chicago who 
lacked any evidence of drug resistance 
using conventional assays, 34 (17%) 
harbored a minority variant containing 
at least one clinically relevant drug 
resistance mutation. As these assays 
can only detect a subset of the known 
drug resistance mutations, the true 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS 
Medicine:
Johnson JA, Li J-F, Wei X, Lipscomb 
J, Irlbeck D, et al. (2008) Minority 
HIV-1 drug resistance mutations are 
present in antiretroviral treatment-
naïve populations and associate with 
reduced treatment efficacy. PLoS 
Med 5(7): e158. doi:10.1371/journal.
pmed.0050158
Using real-time PCR to detect HIV 
resistance mutations present at low 
levels, Jeffrey Johnson and colleagues 
investigate prevalence and clinical 
implications of minority transmitted 
mutations.
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prevalence of transmitted drug 
resistance may have been even greater. 
The second and perhaps more 
worrisome finding comes from a 
retrospective case-control analysis 
of treatment-naïve individuals who 
enrolled in one of two clinical trials. 
All individuals received a standard 
regimen of two nucleoside analogues 
and efavirenz, a non-nucleoside 
reverse transcriptase inhibitor. Of 
the approximately 1,400 individuals 
who received therapy and who lacked 
readily detectable drug resistance at 
baseline, 95 eventually met a standard 
definition of virologic failure (these 
95 patients were selected as the cases 
in the case-control study). Of the 
remaining individuals whose treatment 
did not fail, 221 were selected as 
controls. The frequency of low-level 
drug-resistant variants was higher in 
the cases (seven of 95, or 7.4%) than 
the controls (two of 221, or 0.9%) (p = 
0.004). In a logistic regression analysis, 
the presence of low-frequency drug 
resistance mutations was independently 
predictive of subsequent failure, 
although the small number of controls 
with low-level resistance did not permit 
precise estimates of risk.
Clinical Implications and 
Unresolved Issues
Assuming that further clinical 
evidence confirms this novel association 
between minority resistance mutations 
and HIV treatment failure, should 
we be screening treatment-naïve 
individuals for minority resistance 
variants, and if so, will it be feasible to 
develop commercially viable assays? 
Although the concept of screening 
everyone who starts ART for pre-
existing drug resistance seems logical, 
a close look at the data might suggest 
otherwise. Of the over 1,400 treatment-
naïve patients who received a standard 
regimen of two nucleoside analogues 
and efavirenz, only seven subsequent 
failures would have been avoided by 
screening for the key drug resistance 
mutations (K103N, M184V, or Y181C). 
Also, if one reasonably assumes that the 
prevalence of minority drug-resistant 
variants was the same in all of the 
treatment successes as was present in 
the subset tested, then more treatment 
successes than failures had low levels 
of drug-resistant HIV before starting 
therapy. In terms of identifying patients 
likely to experience treatment failure, 
the positive predictive value of this 
test might therefore be expected to be 
low. Given the considerable expense 
associated with the various methods to 
detect low-level variants, and given the 
challenges of routinely accessing other 
complex but clinically useful assays 
(e.g., assays used to determine which 
coreceptor HIV uses for cell entry), 
it seems unlikely that approaches to 
detect minority variants will become 
widely available in the near future. 
The work of Johnson and colleagues 
also provides important insights into 
HIV pathogenesis, or at least opens 
up new avenues for future research. 
The current accepted wisdom is that 
once resistance is present, it becomes 
permanently integrated in the human 
genome, and will re-emerge under 
subsequent drug pressure. If this is 
so, then it is difficult to explain why 
individuals with detectable resistance 
to efavirenz had a robust response to 
a regimen containing this drug. This 
counterintuitive outcome was even 
more dramatic in a recent analysis of 
efavirenz-treated individuals enrolled in 
clinical trial ACTG 5095 [15]. Using a 
very sensitive allele-specific PCR assay, 
researchers found low levels of certain 
efavirenz-associated mutations in a 
large subset of patients. Most of the 
study participants harboring a resistant 
variant responded well to therapy 
(the assay used in this study was very 
sensitive, and likely detected variants 
that appeared as a consequence of 
natural variation). Similarly, many 
pregnant women administered a single 
dose of nevirapine to prevent HIV 
transmission show transient evidence 
of high-level nevirapine resistance 
[16], yet exposure to single-dose 
nevirapine is not associated with failure 
in subsequent regimens, as long as 
these regimens are initiated at least 
six months after nevirapine exposure 
[17,18]. Collectively, these observations 
challenge the assumption that once 
resistance emerges, it is permanently 
archived in a manner that compromises 
future therapeutic options. 
In summary, a sizable proportion 
of treatment-naïve HIV-infected 
individuals harbor a minority 
population of drug-resistant HIV. In 
some individuals, these infrequent 
variants may reflect natural variability 
and are unlikely to compromise 
treatment, while in the remaining 
individuals these variants likely reflect 
transmission of a virus population 
that has been exposed to suboptimal 
drug pressures. This latter viral 
population can clearly compromise 
future responses in some but not 
all individuals. It remains to be 
determined if the prevalence of these 
presumably transmitted mutations will 
wane with time (as might be expected 
given the general reduction in drug 
resistance among the chronically 
infected population). It also remains to 
be determined whether assays for the 
detection of low-level variants can be 
developed for patient management.  
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